RGNX compared with FATE: revenue, margins and what each company keeps, and the suppliers and customers both name

RGNXRegenxbio Inc.

Mkt capRevenueRevenue

FATEFate Therapeutics Inc

Mkt capRevenueRevenue

Compare

RGNXRegenxbio Inc.

FATEFate Therapeutics Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Co-movers

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Co-movers

daily closes · 500dMethod ›

Moved together

RGNXwithFATE

×0.42co-movement · FATE on RGNX · 500d

r 0.37scale to r 0.75

Shared co-movers3with RGNXwith FATE

RXRXRecursion Pharmaceuticals, Inc.r 0.46r 0.42

CRSPCRISPR Therapeutics AGr 0.44r 0.41

BEAMBeam Therapeutics Inc.r 0.50r 0.37

RGNX, solidFATE, hatched× = co-movement · βr = correlationBar = r to r 0.75Order: weaker of A and BSource: daily closes

RGNXRegenxbio Inc.

7.20▼−2.83%· post 7.20

Mkt cap$475.3MRevenue$108MQ2 FY26Revenue$170MFY25

FATEFate Therapeutics Inc

2.08▼−4.16%· post 2.08

ClosedOct 30 '26

Mkt cap$249.2MRevenue$2MQ2 FY26Revenue$7MFY25

Compare

ClosedOct 30 '26

RGNXRegenxbio Inc.

FATEFate Therapeutics Inc

7.20▼−2.83%post 7.20

Price

2.08▼−4.16%post 2.08

$475.3M

Mkt cap

$249.2M

Q2 FY26$108M

Revenue

$2MQ2 FY26

FY25$170M

Revenue

$7MFY25

RGNX7.20▼−2.83%vsFATE2.08▼−4.16%ClosedOct 30 '26